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Alzheimer’s disease Alzheimer’s treatment 
Cholinesterase inhibitors 
• Second-generation reversible cholinesterase inhibitor 
• Specific acetylcholinesterase enzyme inhibition 
• Anti-inflammatory effect: Ach can inhibit the synthesis of the pro-
inflammatory cytokines in the macrophages cells 
Donepezil 
• Competitive and reversible cholinesterase inhibitor 
• Specific acetylcholinesterase enzyme inhibition 
• Allosteric modulation of nicotinic Ach receptors in the brain 
Galantamine 
• Pseudo-irreversible cholinesterase enzyme 
• Non-specific inhibition since it blocks both butyrylcholinesterase 
and acetylcholinesterase enzymes. Non-selective inhibition is 
associated with peripheral side effects 
Rivastigmine 
• Block the acetylcholinesterase enzyme (AchE), which catalyzes acetylcholine (Ach) degradation. Additionally, 
acetylcholinesterase contains a peripheral locus that promotes Aβ aggregation. If both locus are inhibited, not only 
higher levels of Ach will be reached, but also Aβ aggregation will not be enhanced 
• Show improvement in cognition 
• Indirectly help function and behaviour 
• Do not affect patient’s survival 
• All AchE inhibitors have similar efficacy 
• Generally well tolerated 
• Cholinomimetic adverse effect, especially gastrointestinal 
• Duration effect proved up to 12 months 
• The combination treatment with memantine shows no additional clinical efficacy 
 
Alzheimer is a neurodegenerative disease characterized for a cognitive impairment 
and behavioural disturbances. This pathology is based on a progressive loss of 
cholinergic neurons in the hippocampus and the frontal cortex due to the presence of 
extracellular amyloid plaques of Aβ peptide and the intracellular neurofibrillary 
tangles made of tau protein. Aβ and tau induce inflammation, mitochondrial damage, 
acetylcholine decrease and oxidative stress and, the consequent neurodegeneration. 
 
There is no current cure for Alzheimer’s disease, though several symptomatic drugs 
are available. The cholinesterase inhibitors donepezil, rivastigmine and galantamine 
-together with memantine- are the only pharmacological treatment licensed for 
Alzheimer’s disease. 
The aim of this assay is to describe the anti-acetylcholinesterase drugs in the current 
context and their new applications. Certain disease-modifying drugs are detailed to 
understand why cholinesterase drugs and memantine are the only licensed ones. 
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Fig 3. Nowadays, disease-modifying drugs are being investigated. The image shows some of the most 
important disease-modifying drugs in study and the processes each one modulates. 
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Fig 2. Rivastigmine, donepezil and galantamine inhibit the acetylcholinesterase enzyme, thus, 
increasing the concentration of acetylcholine. Ach binds to muscarinic and nicotinic receptors 
decreasing the formation of Aβ peptide. mAchR also decreases the phosphorilation of tau, and 
nAchR enhances the formation of the soluble form of APP. Ach has anti-inflammatory effects by 
modulating the cytokine synthesis of the macrophages and other PBMC. Throught all this effects, 
cholinesterase inhibitors improve cognitive outcomes. [2] 
• Cholinesterase inhibitors only act on cholinergic symptoms. 
However, all disease-modifying drugs have failed clinical trials. 
Hence, nowadays there is not enough knowledge of the disease to 
be able to modify it.  
• Cholinesterase inhibitors show a greater efficiency when 
administered in the earliest stages of the disease. One proposal 
has been to develop biomarkers available to detect Aβ peptide and 
hyperphosphorylated tau in the blood and the cerebrospinal fluid 
that could recognize the presence of Alzheimer's disease when 
symptoms have not appeared yet. The main disadvantage of this 
approach is the economic cost of these biomarkers. 
• Recently, the anti-inflammatory roll of cholinesterase inhibitors has 
also been elucidated, so α7-nAchR are considered a new 
therapeutic target. 
 
  Bachelor Degree in Biotechnology, UAB                 Contact: campslau@gmail.com 
Conclusions 
